Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

M R Bishop

Showing results (61-70 of 74) with videos related to

Pageof 8
Sort By:
Leukemia|October 20, 2006
Elevation of soluble CD307 (IRTA2/FcRH5) protein in the blood and expression on malignant cells of patients with multiple myeloma, chronic lymphocytic leukemia, and mantle cell lymphomaT Ise, S Nagata, R J Kreitman, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 1, 1997
Hematopoietic recovery after allogeneic blood stem-cell transplantation compared with bone marrow transplantation in patients with hematologic malignanciesZ S Pavletic, M R Bishop, S R Tarantolo, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 1, 1997
Allogeneic-blood stem-cell collection following mobilization with low-dose granulocyte colony-stimulating factorM R Bishop, S R Tarantolo, J D Jackson, et al.
Bone Marrow Transplantation|March 5, 1998
Lymphocyte reconstitution after allogeneic blood stem cell transplantation for hematologic malignanciesZ S Pavletic, S S Joshi, S J Pirruccello, et al.
Bone Marrow Transplantation|April 24, 2012
Ultra-short course sirolimus contributes to effective GVHD prophylaxis after reduced-intensity allogeneic hematopoietic cell transplantationY Fløisand, L Brinch, T Gedde-Dahl, et al.
Cytotherapy|December 9, 2003
Immunological and clinical effects of post-transplant G-CSF versus placebo in T-cell replete allogeneic blood transplant patients: results from a randomized double-blind studyS S Joshi, M R Bishop, J C Lynch, et al.
Bone Marrow Transplantation|April 3, 2012
Clinical outcomes of patients with desmoplastic small round cell tumor of the peritoneum undergoing autologous HCT: a CIBMTR retrospective analysisR J Cook, Z Wang, M Arora, et al.
Bone Marrow Transplantation|July 10, 2012
Neoantigen and tumor antigen-specific immunity transferred from immunized donors is detectable early after allogeneic transplantation in myeloma patientsM Foglietta, S S Neelapu, L W Kwak, et al.
Bone Marrow Transplantation|April 4, 2000
Outcome of allogeneic stem cell transplantation for B cell chronic lymphocytic leukemiaZ S Pavletic, E R Arrowsmith, P J Bierman, et al.
Leukemia|October 19, 2011
Clinical laboratory markers of inflammation as determinants of chronic graft-versus-host disease activity and NIH global severityL Grkovic, K Baird, S M Steinberg, et al.
Pageof 8

Showing results (61-70 of 74) with videos related to

Sort By:
Pageof 8
Leukemia|October 20, 2006
Elevation of soluble CD307 (IRTA2/FcRH5) protein in the blood and expression on malignant cells of patients with multiple myeloma, chronic lymphocytic leukemia, and mantle cell lymphomaT Ise, S Nagata, R J Kreitman, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 1, 1997
Hematopoietic recovery after allogeneic blood stem-cell transplantation compared with bone marrow transplantation in patients with hematologic malignanciesZ S Pavletic, M R Bishop, S R Tarantolo, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 1, 1997
Allogeneic-blood stem-cell collection following mobilization with low-dose granulocyte colony-stimulating factorM R Bishop, S R Tarantolo, J D Jackson, et al.
Bone Marrow Transplantation|March 5, 1998
Lymphocyte reconstitution after allogeneic blood stem cell transplantation for hematologic malignanciesZ S Pavletic, S S Joshi, S J Pirruccello, et al.
Bone Marrow Transplantation|April 24, 2012
Ultra-short course sirolimus contributes to effective GVHD prophylaxis after reduced-intensity allogeneic hematopoietic cell transplantationY Fløisand, L Brinch, T Gedde-Dahl, et al.
Cytotherapy|December 9, 2003
Immunological and clinical effects of post-transplant G-CSF versus placebo in T-cell replete allogeneic blood transplant patients: results from a randomized double-blind studyS S Joshi, M R Bishop, J C Lynch, et al.
Bone Marrow Transplantation|April 3, 2012
Clinical outcomes of patients with desmoplastic small round cell tumor of the peritoneum undergoing autologous HCT: a CIBMTR retrospective analysisR J Cook, Z Wang, M Arora, et al.
Bone Marrow Transplantation|July 10, 2012
Neoantigen and tumor antigen-specific immunity transferred from immunized donors is detectable early after allogeneic transplantation in myeloma patientsM Foglietta, S S Neelapu, L W Kwak, et al.
Bone Marrow Transplantation|April 4, 2000
Outcome of allogeneic stem cell transplantation for B cell chronic lymphocytic leukemiaZ S Pavletic, E R Arrowsmith, P J Bierman, et al.
Leukemia|October 19, 2011
Clinical laboratory markers of inflammation as determinants of chronic graft-versus-host disease activity and NIH global severityL Grkovic, K Baird, S M Steinberg, et al.
Pageof 8